Randomized clinical trials are needed to clarify the optimal agent for reversal of factor Xa inhibitors, and the ongoing ANNEXA-I trial (NCT03661528) will address this gap among patients with intracranial hemorrhage. The gene discussed is F10; the disease is intracranial hemorrhage.